We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · November 30, 2021

Sacubitril/Valsartan vs Standard Medical Therapies in Patients With Heart Failure and Preserved Ejection Fraction

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial
JAMA 2021 Nov 16;326(19)1919-1929, B Pieske, R Wachter, SJ Shah, A Baldridge, P Szeczoedy, G Ibram, V Shi, Z Zhao, MR Cowie

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading